Tempus AI (TEM) Stock

TEM has purchased Ambry Genetics, which broadens its range of testing services and changes the approach to precision medicine.

Tempus AI, Inc. (NASDAQ:TEM) will hold its Q3 2024 Earnings Conference Call on November 4, 2024, at 4:30 PM ET. The call will feature company representatives including Liz Krutoholow from Investor Relations, Eric Lefkofsky, the Founder and CEO, and Jim Rogers, the CFO. Various conference call participants from different financial institutions will also be present.

TEM's results for the third quarter show good performance in different areas. However, the company is still facing losses in its operations.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a top company in artificial intelligence and precision medicine, has announced that it will share its financial results for the third quarter on Monday, November 4, 2024. The earnings conference call will take place at 4:30 p.m. ET on the same day. Additionally, the previously planned conference call for November 7, 2024, has been canceled.

Tempus AI, Inc, a company focused on healthcare technology, has made good progress since it went public in June, doing better than the Nasdaq and AI-related stock portfolios. The company plans to use AI and machine learning to transform healthcare diagnostics, an area that has many opportunities and is not fully explored. However, despite its strong revenue and growing data licensing business, Tempus still has a long way to go before it becomes profitable and is dealing with high operating costs and expenses.

TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.

In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.

The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.

Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.